All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

GSK, Alteogen partner on subcutaneous Jemperli development, $20M upfront, $265M milestones
Licensing deal, oncology, drug delivery, milestone payments - Read more

AAX Biotech, Vascurie collaborate on neuro-oncology antibody characterization using Seqitope platform technology
Research collaboration, neuro-oncology, antibody, drug discovery, R&D - Read more

Pfizer, Novavax partner on Matrix-M adjuvant technology, $30M upfront, $500M milestones
Licensing deal, vaccine, adjuvant technology, milestone payments, royalties - Read more

Datwyler, LTS Device Technologies, Stevanato Group collaborate on large-volume subcutaneous biologics delivery platform
Strategic collaboration, biologics, drug delivery, manufacturing, oncology - Read more

Bayer, Vanderbilt University Medical Center collaborate on five-year cardiovascular and kidney disease therapy development
Research collaboration, cardiovascular, kidney disease, drug discovery, data analytics - Read more

J&J, Isomorphic Labs partner on AI-designed drug discovery, financial terms undisclosed
Research collaboration, AI/ML, drug discovery, large molecules, biologics - Read more

Aspect Biosystems, Novo Nordisk expand diabetes partnership with additional equity investment, milestone payments
Research collaboration, diabetes, cell therapy, 3D bioprinting, milestone payments, equity investment - Read more

Pfizer sell ViiV Healthcare stake to Shionogi in deal worth $2.1 billion
Divestiture, infectious disease, HIV, equity investment - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Tanabe Pharma America's dersimelagon (MT-7117) hits Ph3 primary endpoint for erythropoietic protoporphyria and X-linked protoporphyria
Small molecule, rare disease, melanocortin-1 receptor agonist, erythropoietic protoporphyria - Read more

Moderna and Merck & Co.'s intismeran autogene plus Keytruda maintains 49% risk reduction in advanced melanoma Ph2 study
mRNA vaccine, cancer, therapeutic vaccine, melanoma, combination therapy, PD-1 inhibitor - Read more

Corvus Pharmaceuticals' soquelitinib ITK inhibitor shows improved Ph1 results in moderate-to-severe atopic dermatitis
Small molecule, autoimmune, ITK inhibitor, atopic dermatitis, T-cell modulation - Read more

Reunion Neuroscience presents positive Ph2 data for RE104 (4-OH-DiPT prodrug) in postpartum depression treatment
Small molecule, neurological, psychedelic therapy, postpartum depression, serotonin receptor - Read more

THE GOOD
Fundraises

Exciva raises $59M Series B for neuropsychiatric treatments, Alzheimer's agitation therapy
Neuropsychiatric, Alzheimer disease, clinical-stage, small molecule - Read more

enGene raises $125M debt facility for bladder cancer gene therapy commercialization
Gene therapy, oncology, bladder cancer, clinical-stage, non-viral delivery - Read more

Think Bioscience raises $55M Series A, synthetic biology for undruggable targets
Synthetic biology, small molecule, rare disease, platform technology - Read more

Epidarex Capital raises $67M cornerstone commitment, early-stage life sciences investor
Venture capital, early-stage investor, life sciences, seed funding - Read more [Paywall]

THE GOOD
Investments

Apiject signs lease for North Carolina blow-fill-seal manufacturing facility targeting generic injectable drug shortages
Injectable drugs, drug shortage, operational, manufacturing expansion - Read more

Roche doubles Genentech's North Carolina facility investment to $2B targeting obesity treatments by 2029
Biologic, metabolic disorders, strategic, major transaction - Read more

THE GOOD
Lawsuits

Supreme Court agrees to review Hikma-Amarin 'skinny label' battle over generic Vascepa marketing practices
Small molecule, cardiovascular, regulatory, competitive - Read more

THE GOOD
Mergers & Acquisitions

Worldwide Clinical Trials acquires Catalyst Clinical Research to expand oncology capabilities with early-stage cancer expertise
Oncology, neurological, strategic, major transaction - Read more

GSK acquires RAPT Therapeutics for $2.2B, targeting food allergy market with ozureprubart antibody
Monoclonal antibody, food allergy, strategic, major transaction - Read more

THE GOOD
Product Launches

West Pharmaceutical Services launches Synchrony S1 prefillable syringe system for biologic delivery in 2026
Biologics, drug delivery, operational, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Boundless Bio halts Ph1/2 trial of BBI-355 and BBI-825 combination for oncogene-amplified solid tumors
Small molecule, cancer, kinase inhibitor, solid tumors, protein degrader - Read more

THE BAD
Regulatory

SEC fines former Spero Therapeutics executives $187,500 total for allegedly misleading investors about antibiotic efficacy
Antibiotic, infectious disease, regulatory, financial, operational - Read more

THE UGLY
Politics & Policy

Trump threatens 10% tariffs on eight EU countries over Greenland, risking pharmaceutical trade deal ratification
Trade policy, pharmaceutical industry, regulatory, operational, financial - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here